ProQR Therapeutics (NASDAQ:PRQR)‘s stock had its “neutral” rating reaffirmed by analysts at Chardan Capital in a research note issued to investors on Tuesday.
Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Thursday. Leerink Swann reaffirmed an “outperform” rating and issued a $12.00 price objective (up previously from $10.00) on shares of ProQR Therapeutics in a report on Tuesday, September 26th. JMP Securities upped their price objective on shares of ProQR Therapeutics from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, September 26th. ValuEngine downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of ProQR Therapeutics in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $18.88.
Shares of ProQR Therapeutics (NASDAQ PRQR) opened at $3.00 on Tuesday. ProQR Therapeutics has a 1-year low of $2.75 and a 1-year high of $6.90. The company has a quick ratio of 6.72, a current ratio of 6.72 and a debt-to-equity ratio of 0.20.
Institutional investors have recently modified their holdings of the business. Nine Chapters Capital Management LLC bought a new stake in ProQR Therapeutics in the third quarter worth about $133,000. Wells Fargo & Company MN raised its position in ProQR Therapeutics by 212.6% in the third quarter. Wells Fargo & Company MN now owns 43,226 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 29,400 shares in the last quarter. Janus Henderson Group PLC bought a new stake in ProQR Therapeutics in the second quarter worth about $2,028,000. Sphera Funds Management LTD. raised its position in ProQR Therapeutics by 60.6% in the third quarter. Sphera Funds Management LTD. now owns 530,000 shares of the biopharmaceutical company’s stock worth $2,571,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Artal Group S.A. raised its position in ProQR Therapeutics by 200.0% in the third quarter. Artal Group S.A. now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $7,275,000 after acquiring an additional 1,000,000 shares in the last quarter. Hedge funds and other institutional investors own 31.63% of the company’s stock.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.